Interferon-β/ribavirin

Reactions 1469, p27 - 14 Sep 2013 S Interferon-β/ribavirin Septic shock causing disseminated intravascular coagulation: case report A woman in her 60s [age not stated] developed septic shock, which subsequently caused disseminated intravascular coagulation (DIC), while receiving interferon-β and ribavirin [routes not stated]. The woman was admitted to hospital where she started receiving IV drip infusion interferon-β 6 000 000 IU/day and ribavirin 600 mg/day (morning 200mg and evening 400mg) [route not stated] for chronic hepatitis C. On day 1 of her treatment, she developed pyrexia and she started receiving loxoprofen and rebamipide. She developed inappetence on day 2 of interferon-β and ribavirin, and she started receiving omeprazole and mosapride on day 6. IV drip infusion of interferon-β 6 000 000IU was started after dinner on day 6; the patient was subsequently noted to have significant vomiting, BP of 86/40mm Hg, HR 114 beats/min and a temperature of 41.4°C. Oedema was affecting her intestinal tract wall and gallbladder wall and she was experiencing watery stool. The woman started receiving dopamine to maintain her BP and was admitted to an ICU where she was intubated and mechanically ventilated. She was diagnosed with septic shock and interferon-β and ribavirin were discontinued on day 6. Laboratory investigations showed that her platelet count was reduced; this was attributed to DIC caused by sepsis. Despite treatment, she did not recover and died of multi-organ failure 3 days after interferon-β and ribavirin had been discontinued. Pharmaceuticals and Medical Devices Agency. Important Safety Information -- Interferon Beta (products for administration in combination with ribavirin) and Ribavirin (capsules). Pharmaceuticals and Medical Devices Safety Information : No. 303, Jul 2013. Available from: URL: http://www.pmda.go.jp - Japan 803092755 1 Reactions 14 Sep 2013 No. 1469 0114-9954/13/1469-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved

Upload
nguyenlien
Category

Documents
view
212
download
0

Embed Size (px):

Transcript of Interferon-β/ribavirin

Reactions 1469, p27 - 14 Sep 2013

SInterferon-β/ribavirin

Septic shock causing disseminated intravascularcoagulation: case report

A woman in her 60s [age not stated] developed septic shock,which subsequently caused disseminated intravascularcoagulation (DIC), while receiving interferon-β and ribavirin[routes not stated].

The woman was admitted to hospital where she startedreceiving IV drip infusion interferon-β 6 000 000 IU/day andribavirin 600 mg/day (morning 200mg and evening 400mg)[route not stated] for chronic hepatitis C. On day 1 of hertreatment, she developed pyrexia and she started receivingloxoprofen and rebamipide. She developed inappetence onday 2 of interferon-β and ribavirin, and she started receivingomeprazole and mosapride on day 6. IV drip infusion ofinterferon-β 6 000 000IU was started after dinner on day 6; thepatient was subsequently noted to have significant vomiting,BP of 86/40mm Hg, HR 114 beats/min and a temperature of41.4°C. Oedema was affecting her intestinal tract wall andgallbladder wall and she was experiencing watery stool.

The woman started receiving dopamine to maintain her BPand was admitted to an ICU where she was intubated andmechanically ventilated. She was diagnosed with septic shockand interferon-β and ribavirin were discontinued on day 6.Laboratory investigations showed that her platelet count wasreduced; this was attributed to DIC caused by sepsis. Despitetreatment, she did not recover and died of multi-organ failure3 days after interferon-β and ribavirin had been discontinued.Pharmaceuticals and Medical Devices Agency. Important Safety Information --Interferon Beta (products for administration in combination with ribavirin) andRibavirin (capsules). Pharmaceuticals and Medical Devices Safety Information :No. 303, Jul 2013. Available from: URL: http://www.pmda.go.jp -Japan 803092755